CHA₂DS₂-VASc Score Calculator

Evidence-based stroke risk stratification for patients with atrial fibrillation. Compute the CHA2DS2-VASc score, assess thromboembolic risk, and receive guideline-directed clinical recommendations.

Congestive Heart Failure / LV Dysfunction +1 pt
History of heart failure or left ventricular systolic dysfunction (LVEF ≤ 40%)
Hypertension +1 pt
History of hypertension requiring pharmacological treatment
Diabetes Mellitus +1 pt
Type 1 or Type 2 diabetes requiring oral hypoglycemics or insulin
Stroke / TIA / Thromboembolism +2 pts
Prior stroke, transient ischemic attack, or systemic thromboembolism
Vascular Disease +1 pt
Prior MI, peripheral artery disease, or aortic plaque
? Low Risk (0 pts) : Male, <65, no factors
? Moderate (1 pt) : Male, 65–74, no factors
? High Risk (≥2) : 75+, HTN, DM, prior stroke
? Elderly : 75+, HTN, DM, female
Privacy first: All calculations are performed locally in your browser. No data is sent to any server.

Understanding the CHA2DS2-VASc Score

The CHA2DS2-VASc score is a validated clinical prediction tool used to estimate the risk of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation (AF). It is the cornerstone of stroke risk stratification in AF management, endorsed by major cardiology societies including the European Society of Cardiology (ESC) and the American Heart Association (AHA).

CHA2DS2-VASc = C + H + A2 + D + S2 + V + A + Sc

Congestive heart failure, Hypertension, Age ≥75 (×2), Diabetes, Stroke/TIA/TE (×2), Vascular disease, Age 65–74, Sex category (female)

Clinical Rationale and Development

The CHA2DS2-VASc score was developed as an enhancement of the earlier CHADS2 score to better identify patients at truly low risk of stroke. The original CHADS2 score (Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke/TIA ×2) categorized many patients as "moderate risk" (score 1), leading to clinical uncertainty regarding anticoagulation. The CHA2DS2-VASc score adds additional risk factors — age 65–74 (1 point), vascular disease (1 point), and female sex (1 point) — to refine risk stratification, particularly in the low-to-moderate risk range.

Data from large cohort studies, including the Framingham Heart Study and the SPAF (Stroke Prevention in Atrial Fibrillation) trials, informed the weighting of each risk factor. The score's predictive performance has been validated in multiple independent cohorts across diverse populations, demonstrating robust calibration for both ischemic stroke and systemic embolism.

Risk Factor Breakdown

Risk Factor Abbreviation Points Clinical Definition
Congestive Heart Failure / LV Dysfunction C 1 Current or prior heart failure, or LVEF ≤ 40%
Hypertension H 1 History of hypertension requiring drug therapy
Age ≥ 75 years A2 2 Advanced age is a potent independent predictor
Diabetes Mellitus D 1 Type 1 or type 2 diabetes on treatment
Stroke / TIA / Thromboembolism S2 2 Prior ischemic stroke, TIA, or systemic embolism
Vascular Disease V 1 Prior MI, PAD, or aortic atherosclerotic plaque
Age 65 – 74 years A 1 Moderate age is a significant risk modifier
Female Sex Sc 1 Female sex is a risk factor, especially at age ≥ 65

Risk Stratification and Clinical Guidance

The CHA2DS2-VASc score stratifies patients into three broad risk categories, directly informing anticoagulation decisions:

Low Risk

Score 0 (men) or 1 (women*): Annual stroke risk ~0.2%. Anticoagulation is not routinely recommended. Consider re‑evaluation annually.

*Female sex alone (score 1) in the absence of other risk factors does not mandate anticoagulation.
Moderate Risk

Score 1 (men) or 2 (women): Annual stroke risk ~0.6–2.2%. Anticoagulation should be considered after weighing patient preference and bleeding risk.

Oral anticoagulation (OAC) is generally preferred for most patients in this category.
High Risk

Score ≥ 2 (men) or ≥ 3 (women): Annual stroke risk ≥ 3.2%. Anticoagulation is strongly recommended with a vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC).

DOACs are preferred over VKAs in most patients due to better safety profiles.
2024 ESC Guidelines for the Management of Atrial Fibrillation: The CHA2DS2-VASc score is recommended for initial stroke risk assessment. For patients with a score of ≥ 2 (men) or ≥ 3 (women), oral anticoagulation is indicated. For patients with score 1 (men) or 2 (women), OAC should be considered. The guidelines emphasize shared decision‑making and incorporation of bleeding risk (HAS‑BLED score).

How This Calculator Works

  1. Select age group – <65, 65–74, or ≥75 years.
  2. Select sex – male or female.
  3. Check all applicable risk factors – heart failure, hypertension, diabetes, stroke/TIA, vascular disease.
  4. The calculator sums the points automatically and displays your total CHA2DS2-VASc score.
  5. The tool provides a risk category, annual stroke risk estimate, and a guideline‑based clinical recommendation.
  6. The interactive canvas visualizes your score on a risk gradient for intuitive understanding.

Clinical Case Examples

Case 1: Low Risk

Patient: 62‑year‑old male, no prior cardiovascular disease, normotensive, non‑diabetic, no stroke history. CHA2DS2-VASc score = 0. Annual stroke risk ~0.2%. No anticoagulation recommended. Lifestyle modification and annual reassessment advised.

Case 2: Moderate Risk

Patient: 68‑year‑old female with hypertension and diabetes. No stroke or heart failure. CHA2DS2-VASc score = 3 (Age 65–74: 1, Female: 1, HTN: 1, DM: 1). Annual stroke risk ~3.2%. Anticoagulation with a DOAC is recommended after discussion of bleeding risk.

Case 3: High Risk

Patient: 78‑year‑old male with prior stroke, hypertension, and heart failure. CHA2DS2-VASc score = 6 (Age ≥75: 2, Stroke: 2, HTN: 1, CHF: 1). Annual stroke risk ~9.7%. Strong indication for anticoagulation. Direct oral anticoagulant preferred over warfarin.

Comparison with CHADS2 Score

Feature CHADS2 CHA2DS2-VASc
Number of risk factors 5 8
Age 65–74 Not included 1 point
Vascular disease Not included 1 point
Female sex Not included 1 point
Age ≥75 1 point 2 points
Stroke/TIA 2 points 2 points
Maximum score 6 9
Risk stratification Less granular at low scores More refined, better identifies truly low risk

The CHA2DS2-VASc score has largely replaced CHADS2 in clinical practice due to its superior ability to identify patients who genuinely do not benefit from anticoagulation.

Limitations and Considerations

  • Bleeding risk: The CHA2DS2-VASc score does not incorporate bleeding risk. Clinicians should also assess bleeding risk using tools like HAS‑BLED or HEMORR2HAGES.
  • Valvular AF: The score is validated for non‑valvular AF. Patients with rheumatic mitral stenosis or mechanical heart valves require different management.
  • Dynamic nature: Risk factors such as hypertension and diabetes can change over time. The score should be re‑assessed periodically (e.g., annually).
  • Ethnic variations: Some studies suggest that the score may over‑ or under‑estimate risk in certain ethnic groups; clinical judgment remains paramount.
  • Patient preference: Anticoagulation decisions should be shared with patients, considering their values, preferences, and lifestyle.

Frequently Asked Questions

Your score estimates your risk of stroke or systemic embolism over the next year, based on your age, sex, and cardiovascular risk factors. Higher scores indicate higher risk and stronger indication for anticoagulation.

In men, a score of 0 indicates low risk (annual stroke ~0.2%), and anticoagulation is not routinely recommended. In women, a score of 1 (due to sex alone) also does not require anticoagulation. However, your risk should be re‑evaluated annually as age and new risk factors may develop.

The score has been validated in numerous large‑scale studies and is widely accepted as a reliable tool for stroke risk stratification in atrial fibrillation. However, it is a statistical prediction, not a certainty. Individual patient factors may modify risk.

CHA2DS2-VASc predicts thromboembolic (stroke) risk, while HAS‑BLED predicts bleeding risk. Both scores are used together in clinical decision‑making: if a patient has a high CHA2DS2-VASc score (indicating high stroke risk), the benefit of anticoagulation usually outweighs the bleeding risk, even if HAS‑BLED is elevated.

This tool is designed for non‑valvular atrial fibrillation. Patients with rheumatic mitral stenosis or mechanical heart valves require different risk stratification and anticoagulation strategies (usually warfarin). Consult your cardiologist.

Authoritative resources include the ESC Clinical Practice Guidelines for Atrial Fibrillation, the AHA/ACC/HRS AF Guideline, and patient‑facing materials from the American Heart Association.

Rooted in evidence‑based cardiology – This tool is built upon the validated CHA2DS2-VASc score as published by Lip et al. (2010) and endorsed by the ESC, AHA, and other major cardiology societies. The implementation follows the original scoring algorithm and risk estimates derived from large‑scale cohort analyses. Reviewed by the GetZenQuery tech team, last updated July 2026.

References: Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‑based approach. Chest 2010.; ESC 2024 AF Guidelines; AHA/ACC/HRS 2019 AF Guideline (updated).